Vaccitech plc

Vaccitech is a clinical stage T cell immunotherapy and vaccine company developing products to treat and prevent infectious disease and cancer. The company’s proprietary heterologous prime-boost platform comprises Chimpanzee Adenovirus Oxford (ChAdOx) and Modified Vaccinia Ankara (MVA), two non-replicating viral vectors which safely mimic viral infection in human cells and elicit high magnitude, durable, targeted CD8+ and CD4+ T cell responses and antibodies to clear foreign pathogens and tumours.